This was the deck I used for a short talk I gave on social customer care at the Social Business Meet-up #2 organised by Will McInnes (@willmcinnes).
The deck centres on the Open Public Services whitepaper published in 2011, and the backdrop against which it was published. The white paper talks about decentralising service to the 'lowest appropriate level'. My belief is that there is a fundamental disconnect between the understanding that decentralisation can be and is a conscious decision on the part of the government, versus the fact that people are simply decentralising at will.
This was the deck I used for a short talk I gave on social customer care at the Social Business Meet-up #2 organised by Will McInnes (@willmcinnes).
The deck centres on the Open Public Services whitepaper published in 2011, and the backdrop against which it was published. The white paper talks about decentralising service to the 'lowest appropriate level'. My belief is that there is a fundamental disconnect between the understanding that decentralisation can be and is a conscious decision on the part of the government, versus the fact that people are simply decentralising at will.
mHealth Israel_Yoheved Novogroder-Shoshan_IP Best Practices: Tips for mHeal...Levi Shapiro
IP Best Practices: Tips for mHealth Companies, Investors and Acquirers. Presentation by Yoheved Novogroder-Shoshan, Partner at the law firm of Yigal Arnon, June 29th at the mHealth Israel Investors Summit. Includes checklist of five things Founders / Inventors can do to protect their Intellectual Property and increase value.
An introduction to the mHealth opportunity for Street Medicine (Draft slides)3GDR
Presented at the Irish Street Medicine Symposium by David Doherty (@mHealth) on the 24th September 2016 at University College Cork.
More information/links:
https://mhealthinsight.com/2016/08/22/streetmedicine/
Q4-2013 Update on the German Telecoms-MarketDSP-Partners
English version
115 million Mobile Subscribers/SIMs on the German market per Q4/2013, up 2 million since Q4/2012. This accounts for 1,4 SIMs per person in Q4/2013.
In Broadband, Deutsche Telekom is the clear market-leader with 12,4 million DSL-lines. Kabel Deutschland takeover by Vodafone (approved 9/2013) created a clear #2 with 5 million broadband lines (3m DSL, 2m cable broadband lines).
-> Learn more about the German Telecoms-Market at: http://bit.ly/DSP-Telecoms
Deutsche Version
Im vierten Quartal 2013 befanden sich 115 Millionen SIM-Karten auf dem deutschen Markt, dies sind 2 Millionen mehr als im vierten Quartal 2012. Somit besitzt jeder Deutsche im Durchschnitt 1,4 SIM-Karten.
Im Festnetz entsteht durch die genehmigte Fusion von Kabel Deutschland und Vodafone eine neue Nummer 2 mit 5 Millionen Breitbandkunden, davon 3 Millionen DSL-Anschlüsse und 2 Millionen Kabelanschlüsse. Die Deutsche Telekom führt den Markt jedoch weiter deutlich an mit 12,4 Millionen DSL-Anschlüssen.
-> Mehr zum deutschen Telekommunikationsmarkt unter: http://bit.ly/DSP-Telecoms
mHealth for Healthcare Professionals Digital Health Summit Turkey3GDR
Presented by David Doherty on 19 December 2015
For more info see http://dhsturkey.com #DHSTurkey
For a recent similar video (from the World Diabetes Congress in Vancouver):
https://www.youtube.com/watch?v=uH8SxqRCeIM
Visualizing Healthcare Data: Information Design Best Practices (eHealth 2012 ...Stefan Popowycz
This is my eHealth 2012 presentation will focuse on the principles behind information design and how visualization best practices can be leveraged within context of healthcare data. It illustrates theory in action, by drawing specific attention to the successful public facing solution, the 2012 Canadian Hospital Reporting Project (CHRP). The CHRP tool is a pan-Canadian external facing solution with an audience of over 3000+ users; it received over 25,000 impressions in the first 24 hours, and was called by the Toronto Star as “an innovative online tool that is being heralded as the most advanced of its kind in the world.”
mHealth Israel_Yoheved Novogroder-Shoshan_IP Best Practices: Tips for mHeal...Levi Shapiro
IP Best Practices: Tips for mHealth Companies, Investors and Acquirers. Presentation by Yoheved Novogroder-Shoshan, Partner at the law firm of Yigal Arnon, June 29th at the mHealth Israel Investors Summit. Includes checklist of five things Founders / Inventors can do to protect their Intellectual Property and increase value.
An introduction to the mHealth opportunity for Street Medicine (Draft slides)3GDR
Presented at the Irish Street Medicine Symposium by David Doherty (@mHealth) on the 24th September 2016 at University College Cork.
More information/links:
https://mhealthinsight.com/2016/08/22/streetmedicine/
Q4-2013 Update on the German Telecoms-MarketDSP-Partners
English version
115 million Mobile Subscribers/SIMs on the German market per Q4/2013, up 2 million since Q4/2012. This accounts for 1,4 SIMs per person in Q4/2013.
In Broadband, Deutsche Telekom is the clear market-leader with 12,4 million DSL-lines. Kabel Deutschland takeover by Vodafone (approved 9/2013) created a clear #2 with 5 million broadband lines (3m DSL, 2m cable broadband lines).
-> Learn more about the German Telecoms-Market at: http://bit.ly/DSP-Telecoms
Deutsche Version
Im vierten Quartal 2013 befanden sich 115 Millionen SIM-Karten auf dem deutschen Markt, dies sind 2 Millionen mehr als im vierten Quartal 2012. Somit besitzt jeder Deutsche im Durchschnitt 1,4 SIM-Karten.
Im Festnetz entsteht durch die genehmigte Fusion von Kabel Deutschland und Vodafone eine neue Nummer 2 mit 5 Millionen Breitbandkunden, davon 3 Millionen DSL-Anschlüsse und 2 Millionen Kabelanschlüsse. Die Deutsche Telekom führt den Markt jedoch weiter deutlich an mit 12,4 Millionen DSL-Anschlüssen.
-> Mehr zum deutschen Telekommunikationsmarkt unter: http://bit.ly/DSP-Telecoms
mHealth for Healthcare Professionals Digital Health Summit Turkey3GDR
Presented by David Doherty on 19 December 2015
For more info see http://dhsturkey.com #DHSTurkey
For a recent similar video (from the World Diabetes Congress in Vancouver):
https://www.youtube.com/watch?v=uH8SxqRCeIM
Visualizing Healthcare Data: Information Design Best Practices (eHealth 2012 ...Stefan Popowycz
This is my eHealth 2012 presentation will focuse on the principles behind information design and how visualization best practices can be leveraged within context of healthcare data. It illustrates theory in action, by drawing specific attention to the successful public facing solution, the 2012 Canadian Hospital Reporting Project (CHRP). The CHRP tool is a pan-Canadian external facing solution with an audience of over 3000+ users; it received over 25,000 impressions in the first 24 hours, and was called by the Toronto Star as “an innovative online tool that is being heralded as the most advanced of its kind in the world.”
Draft Slide Deck for the IoTSummit.ie 17 June 2015: How the IoT's will impact...3GDR
Draft Slide Deck for the IoTSummit.ie 17 June 2015: How the IoT's will impact on the delivery of Healthcare
Talk discusses what's happening in the Healthcare industry as the Internet evolves into a device dominated network.
HealthXL is the global clearing house for innovation in healthcare. We catalyse collaboration between leading brands in healthcare and the most exciting tech companies to improve the lives of millions of people.
Our partners are Bupa, Cleveland Clinic, Becton Dickinson, IBM, ICON, ResMed, Janssen Healthcare Innovation, Linde Healthcare, Novartis, Partners HealthCare, Silicon Valley Bank and EY.
Together with our partners we establish audacious goals (Moonshots) to work towards within healthcare. Then we search for innovators in digital health that can work with us and our partners to achieve those Moonshots. We help them find each other, create business partnerships and facilitate their relationship through collaboration
Slides for lecture by David Doherty (about.me/mHealth) to the Medical Students at University College Dublin on Thursday 22 March 2018.
Full details and Video:
https://mhealthinsight.com/2018/03/22/how-would-the-bornmobile-generation-redesign-medicine-and-whats-the-future-role-of-the-doctor/
Slides for WearablesLondon talk on the Wearables Opportunity for Seniors3GDR
Slides accompanying the talk given by 3G Doctor's David Doherty at Wearables London on the 25th June 2015:
http://www.meetup.com/Wearables-London/
http://about.me/mHealth
Similar to David Doherty presentation slide deck from Digital Health Summit Turkey 2013 (20)
HorseTech Conference Cheltenham 15/16 March 20223GDR
Speakers who will present on 15-16th March 2022 at the HorseTech Conference Cheltenham (and can be watched via the completely FREE livestream). For full details and to register:
https://horsetechconference.com/cheltenham/
DOCTORS AND SOCIAL MEDIA webinar (delivered by Liz Price, MDDUS senior risk a...3GDR
These slides were used for a MDDUS webinar that aimed to explore the legislative and regulatory risks involved in doctors personal and professional use of social media, and in relation to responding to and engaging with patients via this media.
The objectives were to raise awareness of the common medicolegal risks associated with doctors personal use of social media.
To raise awareness of the common medicolegal risks associated with doctors professional use of social media. To explore ways in which doctors can most appropriately respond to patient feedback and contacts via online platforms.
Participants are equipped to apply the knowledge gained in the webinar to risk assess and safely manage their online activities.
Provides guidance to enable improvement of personal practice in this area:
Royal Pharmaceutical Society UCL School of Pharmacy New Year Lecture 20193GDR
Diabetes and the Pharmacy Army
Philip Newland-Jones
Consultant Pharmacist Diabetes & Endocrinology
University Hospital Southampton NHS Foundation Trust
Mobile Health: the enable of Empowered Patients3GDR
Draft of slides for talk by David Doherty (coFounder, 3GDoctor) at the "Transforming Community Pharmacies in to High Street Clinics" Conference in London on the 15th November 2018.
For more information please visit:
https://mhealthinsight.com/2018/10/28/join-us-at-transforming-community-pharmacies-in-to-high-street-clinics/
Mobile Health: the enable of Empowered Patients3GDR
Draft of slides for talk by David Doherty (coFounder, 3GDoctor) at the "Transforming Community Pharmacies in to High Street Clinics" Conference in London on the 15th November 2018.
Slides for lecture by David Doherty (about.me/mHealth) to the Medical Students at University College Dublin on Thursday 29th March 2018.
Full details and Video:
https://mhealthinsight.com/2018/03/22/how-would-the-bornmobile-generation-redesign-medicine-and-whats-the-future-role-of-the-doctor/
eHealth Ireland & Northern Ireland Connected Health Ecosystem
members of the ECHAlliance International Ecosystem Network
Cross Border Collaboration Projects in Action Alan Connor, mPower Programme Manager, NHS24
Notes on a talk on “Pricing and evaluating Orphan Drugs – present and future”...3GDR
The following slides are notes made by David Doherty following a very interesting presentation on “Pricing and evaluating Orphan Drugs – present and future” provided by Goran Medic, Market Access Manager Europe at Horizon Pharma Plc at the Pharma Pricing & Market Access Europe Conference in London (the world’s largest gathering of pharmaceutical pricing, market access and reimbursement professionals) on the 23rd February 2017.
Deriving more value from real world evidence to ensure timely access of medic...3GDR
Dr Sarah Wamala Andersson, Consultant, Real world evidence and value-based medicines
Pharma Pricing & Market Access Congress 2017 22 February 2017 London
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
50. David Doherty
Healthcare roles have
been key to the rapid
adoption of Mobile
http://mobihealthnews.com/4027/successful-mhealth-applications-are-already-
here/